Melanoma growth is driven by malignant melanoma-initiating cells (MMIC) 
Introduction
Human malignant melanoma is a highly aggressive and drug-resistant cancer that is usually refractory to systemic therapy. Identification of undifferentiated subpopulations with embryonic-like plasticity within this malignancy has pointed to the existence of aggressive cell subsets that may be responsible for melanoma initiation, tumor progression, and resistance to chemotherapy (1) (2) (3) (4) . Recently our laboratory identified tumorigenic malignant melanoma-initiating cells (MMIC) capable of self-renewal and differentiation that can be prospectively enriched on the basis of preferential expression of the ATP-binding cassette (ABC) member ABCB5 (5-8), a chemoresistance gene (5, 9, 10) . ABCB5 þ tumor cells, which were found to range in frequency from 1.6% to 20.4% in human melanomas (7) , correlate with malignant disease initiation and metastatic progression in tumor xenotransplantation models involving either NOD/SCID or NOD/SCID interleukin-2 receptor (IL-2R) g-chain null (NSG) murine recipients (7, 11, 12) and in clinical studies of human melanoma patients (7, (13) (14) (15) according to results from several laboratories. Consistent with these findings, the ABCB5 gene is also preferentially expressed by in vitro self-renewing, clonogenic melanoma subpopulations (16) , melanoma cell lines of metastatic as opposed to primary tumor origin (17) , and melanomas with high in vivo tumorigenic capacity in human to murine xenotransplantation models (18, 19) . Furthermore, ABCB5 is downregulated in human melanoma cells upon induction of terminal differentiation (20) . Importantly, ABCB5 þ melanoma cells can be therapeutically targeted in experimental tumor xenotransplantation models, with specific killing of this tumor subpopulation resulting in inhibition of tumor growth (7) . MMIC-enriched ABCB5 þ melanoma subpopulations trigger tumorigenesis and promote neoplastic progression through enhanced self-renewal and proliferative capacity (7) . Preferential evasion of host antitumor immunity, a determinant of tumor growth (4, (21) (22) (23) (24) (25) , represents an additional mechanism responsible for the enhanced tumorigenicity of ABCB5 þ melanoma subpopulations (8) . Tumor functions relevant to the generation of a protumorigenic microenvironment through differentiation (4, 26) could represent additional mechanisms for the preferential tumorigenicity of ABCB5 þ melanoma subpopulations. In this regard, we recently found that ABCB5 þ human melanoma cells are specifically associated with vasculogenic mimicry (VM), a phenomenon whereby more primitive and aggressive melanoma cells express endothelial genes and related proteins [TIE1 and CD144 (VE-cadherin), but not CD31] and in situ develop patterned networks composed of periodic acid-Schiff (PAS) and laminin-reactive basement membranes lined by tumor cells (27) . Our previous results showed that subpopulations of ABCB5 þ human melanoma cells preferentially express the vasculogenic differentiation markers TIE1 and CD144 (7) . Expression of TIE1 and CD144 by ABCB5 þ melanoma subpopulations was confirmed by gene and protein expression analyses of genetically tracked fluorescent melanoma xenografts (7) . Furthermore, human tumor cells that coexpressed ABCB5 and TIE1/CD144 were distinct from mature CD31 þ tumor endothelium in clinical patient tumors and experimental melanomas in serial xenotransplantation experiments (7) . Although it remains currently unknown whether VM might represent, in addition to conventional angiogenesis, a related yet independent mechanism of tumor perfusion, it has been established that VM characterized by expression of TIE1 and CD144 relates to melanoma aggressiveness (28) and that associated PAS-positive VM networks that also express laminin represent a biomarker in human melanomas associated with increased clinical mortality (29) . The molecular mechanisms governing melanoma VM, and their potential relationship to MMIC and melanoma growth, are largely unknown. We hypothesized that global gene expression analyses of tumorigenic, MMIC-enriched ABCB5 þ melanoma subpopulations, capable of VM, vis-a-vis ABCB5 À melanoma bulk populations, might serve to identify molecular signaling pathways responsible for VM and, as a result, allow investigation of their potential relevance to melanoma growth.
Materials and Methods

Melanoma cells and culture methods
Authenticated human melanoma cell lines were obtained from the NCI/NIH Developmental Therapeutics Program or American Type Culture Collection (ATCC) and melanoma cell lines were cultured and passaged for fewer than 6 months as described (5) (6) (7) . Clinical cutaneous melanoma cells were derived from surgical specimen according to Institutional Review Board-approved human subjects research protocols as described previously (7) . Human umbilical vein endothelial cells (HUVEC) were purchased from Invitrogen and cultured according to the supplier's protocol.
Cell isolation
populations were generated by removing ABCB5 þ cells or VEGFR-1 þ cells by magnetic bead cell sorting with anti-ABCB5 (6) or anti-VEGFR-1 monoclonal antibody (mAb; R&D Systems) as described (7) . Assessment of purity of melanoma cell isolates and determination of cell viability following magnetic cell sorting were carried out and yielded results as described previously (7).
RNA extraction and real-time quantitative PCR Total RNA was isolated from ABCB5 þ and ABCB5 À human melanoma cells or HUVEC cultures with the RT 2 qPCR Grade RNA isolation kit (SABiosciences). Standard cDNA synthesis reactions were carried out and the reverse transcriptase product was amplified by gene-specific primer pairs; b-actin was used as a normalizing control. The primers for ABCB5 detection were as described previously (5), primers for VEGFR-1 (Genbank accession no. NM_002019) detection were 5 0 -GACCTGGAGTTACCCTGATGAAA-3 0 (forward) and 5 0 -GGCATGGGAATTGCTTTGG-3 0 (reverse) and for b-actin detection 5
0 -CCTGGCACCCAGCACAAT-3 0 (forward) and 5 0 -AGTACTCCGTGTGGATCGGC-3 0 (reverse). Samples were assayed by Sybergreen chemistry and kinetic PCR (ABI 7300 Sequence Detector; Applied Biosystems). The relative amounts of transcripts were analyzed by the 2 (ÀDDCt) method as described previously (5, 7, 30) . Statistical differences between mRNA expression levels were determined by the nonparametric Mann-Whitney test. A 2-sided value of P < 0.05 was considered significant.
Global gene expression microarray analyses
Microarray analyses were carried out on purified ABCB5 þ (n ¼ 5) and ABCB5 À (n ¼ 5) cell subsets derived from the established human melanoma cell lines G3361 and A375 and from 3 distinct clinical melanoma specimen previously characterized in our laboratory with regard to ABCB5 expression and MMIC phenotype in human melanoma xenotransplantation assays (7) . Total RNA was extracted, processed, and hybridized as described previously (30) onto Affymetrix human HG-U133Plus2 GeneChip microarrays (Affymetrix). Statistical analysis of microarray results was carried out as described previously (30) . The expression data set in its entirety is available through GEO (Gene Expression Omnibus) DataSets (accession number GSE26569). Functional gene networks were generated by Ingenuity Pathways Analysis (Ingenuity Systems; www.ingenuity.com) by mapping each gene identifier to its corresponding gene object in the Ingenuity Pathways Knowledge Base. These focus genes were overlaid onto a global molecular network developed from information contained in the Ingenuity Pathways Knowledge Base. Focus gene networks were then algorithmically generated on the basis of their connectivity and subsequently analyzed to identify the biological functions that were most significant to the genes in the network.
Western analysis
Total cell lysates were harvested from logarithmically growing cultures of the human melanoma cell lines MALME-3M, SK-MEL-2, SK-MEL-5, SK-MEL-28, UACC-62, UACC-257, M14, and MDA-MB-435 and analyzed by 8% SDS-PAGE and Western assay to detect relative levels of ABCB5 (mAb 3C2-1D12; ref. 6 ) and a-tubulin (mAb clone DM1A; Sigma-Aldrich) by LI-COR Odyssey IR imaging system densitometry. Western blots for the analysis of VEGFR-1 expression were carried out with rabbit anti-VEGFR-1 antibody (Epitomics) or mouse antib-actin antibody as a control (Cell Signaling Technology) and horseradish peroxidase-linked secondary goat anti-mouse antibody or goat anti-rabbit antibody (Sigma), respectively. The reactive bands were detected by the addition of chemoluminescent substrate (ECL; GE Healthcare Bio-Sciences Corp.).
Flow cytometry
The analysis of cell surface coexpression of ABCB5 with VEGFR-1 was carried out by dual-color flow cytometry as described (7), using anti-ABCB5 mAb or isotype control mAb, followed by counterstaining with APC-conjugated donkey anti-mouse IgG secondary Ab as above, and phycoerythrin (PE)-conjugated anti-VEGFR-1 mAb (R&D Systems) or PEconjugated isotype control mAb (BD PharMingen). Statistical differences between expression levels of markers were determined by the nonparametric Mann-Whitney test. A 2-sided value of P < 0.05 was considered significant.
In vitro vasculogenic differentiation and tube formation assays VEGF-dependent induction of CD144 and of von Willebrand factor (VWF) expression and formation of capillary-like tube structures by human melanoma cells was assayed on growth factor-reduced Matrigel, a basement membrane matrix preparation (BD Biosciences). Purified ABCB5 þ or ABCB5 À or unsegregated human melanoma cells were seeded into culture slide wells in medium 199 containing 5% fetal calf serum (31) in the presence or absence of VEGF (100 ng/mL). After 48-hour incubation, cells were fixed and then incubated with rabbit anti-CD144 polyclonal Ab (Bethyl Laboratories) or rabbit anti-VWF polyclonal Ab (Dako) overnight at 4 C. Subsequently, the cells were incubated with goat anti-rabbit Texas red-conjugated secondary Ab (Jackson ImmunoResearch Laboratories), washed and mounted in Vectashield (Vecta Laboratories) supplemented with 4 0 ,6-diamidino-2-phenylindole and then analyzed by fluorescent microscopy as described previously (8) . For tube formation assays, melanoma cells were seeded into culture slide wells as above and then pretreated with medium alone, rabbit anti-VEGFR-1 Ab (10 mg/mL; Santa Cruz Biotechnology), or rabbit isotype control Ab (10 mg/mL; BD Biosciences) prior to stimulation with VEGF (100 ng/mL). Tube formation was detected by phase-contrast microscope (Nikon Eclipse TE 300 microscope) after 24 hours of incubation. For quantitative analysis of tube formation and length and for the determination of CD144 and VWF expression at 48 hours, 3 randomly selected microscopy fields were photographed per experimental condition. Tube formation was analyzed by Image J software available from the NIH Web site as described previously (32) . For quantification of CD144 and VWF expression, positive cells were counted by Neurolucida 8.10 software (MBF Bioscience). Differences among groups were analyzed by oneway ANOVA followed by Bonferroni post hoc tests. Differences with P < 0.05 values were considered statistically significant.
Immunohistochemistry and immunofluorescence
The following primary Abs were used: rat anti-laminin B2 (Abcam), mouse anti-ABCB5 (5-7), rabbit anti-CD271 (RayBiotech), and goat anti-VEGFR-1 (R&D Systems). Isotypematched irrelevant Abs served as negative controls. The secondary Abs were goat anti-rat IgG-HRP and horse anti-mouse IgG-HRP (Biolegend) for immunohistochemistry and Alexa Fluor 594 goat anti-mouse IgG1, Alexa Fluor 488 goat antimouse IgG2a, Alexa Fluor 594 donkey anti-mouse IgG, Alexa Fluor 488 donkey anti-goat IgG3, Alexa Flour 488 donkey antimouse IgG, and Alexa Fluor 594 donkey anti-rabbit IgG (Invitrogen) for immunofluorescence staining. Immunohistochemistry was carried out by the 2-step horseradish peroxidase method as described previously (7). Immunofluorescence double staining was carried out as described previously (7). Quantitative analysis of laminin expression (percent positively staining area of sections) was carried out by the ImageJ program, and statistical differences between expression levels were determined by the nonparametric Mann-Whitney test.
In situ hybridization ABCB5 RNA probes were prepared as follows: PCR-derived RNA probe templates were synthesized by introducing the T7 promoter into the antisense strand and the SP6 promoter into the sense strand. The primer pair (5 0 -TAATACGACTCACTA-TAGGGATGTCTGGCTTTTTCCCTTCTTGAC-3 0 ) and (5 0 -GATTT AGGTGACACTATAGAAATTCAAGCTGGACGAATGA CCCCA-3 0 ) was used to generate the DNA template for antisense and sense RNA probes spanning 200 base pairs of human ABCB5 cDNA. RNA probe labeling with digoxigenin (DIG) and in situ hybridizations (ISH) were carried out as described previously (33) .
Melanoma transfection with VEGFR-1 short hairpin RNA Two distinct shRNA plasmids targeting human VEGFR-1 mRNA, and negative control short hairpin RNA (shRNA) plasmids without homology to human mRNA, also containing the green fluorescent protein (GFP) marker, were purchased from SuperArray (SureSilencing; SuperArray). Human melanoma cells were transfected with the SuperFECT transfection reagent (SuperArray) according to the manufacturer's instructions. For determination of VEGFR-1 knockdown efficiency by real-time PCR or Western blotting, cells were harvested and total RNA was purified 48 hours posttransfection or cell lysates were prepared 96 hours posttransfection, respectively. Cells were harvested for use in xenotransplantation assays 24 hours posttransfection, when flow cytometric GFP fluorescence measurements at the Fl1 spectrum showed more than 90% transfection efficiency in both VEGFR-1 shRNAs-and control shRNA-transfected melanoma cultures.
Animals
BALB/c nude mice, NOD/SCID mice, and NSG mice were purchased from The Jackson Laboratory. Mice were maintained in accordance with the institutional guidelines of Children's Hospital Boston and Harvard Medical School and experiments were carried out according to the approved experimental protocols.
Human to mouse melanoma xenotransplantation
Human to mouse melanoma xenografts were established by subcutaneous injection of human G3361 or A375 or of clinical patient-derived human melanoma cells in NOD/SCID or NSG mice as described previously (7, 11 or 3 weeks (shRNA-transfected xenografts) after tumor cell inoculation. Differences in tumor volume (TV), determined as described previously (7), were statistically compared by the nonparametric Mann-Whitney test, with a 2-sided value of P < 0.05 considered significant.
Results
VEGFR-1 is preferentially expressed by ABCB5 þ human melanoma cells
Melanoma growth is driven by MMIC identified by expression of ABCB5, as previously shown in human melanoma to NOD/SCID mouse tumor xenotransplantation models (7). Higher frequencies of cells capable of tumor initiation have been observed in side-by-side comparative studies in more severely immunocompromised NSG xenograft recipients (22 (Fig. 1A) , showing significant enrichment of tumorigenic capacity of ABCB5 þ MMIC even in more immunocompromised NSG mice (P < 0.05). Remarkably, we found the MMIC markers ABCB5 (7) and CD271 (34) preferentially coexpressed on the same tumor subpopulation in clinical human melanoma specimens (Fig. 1B) (Fig. 1D, 1 .9 AE 0.5-fold vs. 0.3 AE 0.1-fold expression compared with detection in HUVEC, mean AE SE, P < 0.001) and was also shown by dual-color flow cytometry at the protein level (9.6% AE 2.2% vs. 0.9% AE 0.2% of cells, respectively, mean AE SE, n ¼ 10, P < 0.001; Fig. 1E ). In addition, immunofluorescence double staining analysis of clinical human melanoma specimens, clinical human melanoma xenografts, and human melanoma cell line xenografts, using human VEGFR-1-specific mAb, also revealed specific coexpression of VEGFR-1 on ABCB5 þ melanoma cells in situ (Fig. 1F) . negative VEGFR-1 expression (P < 0.0001) ( Fig. 2A) . Moreover, preincubation with a blocking mAb to VEGFR-1 abrogated the ability of VEGF to induce CD144 expression in human melanoma cells (CD144 positivity 1.8% AE 1.3% in VEGFR-1 mAb-treated cultures vs. 42.5% AE 7.2% or 45.8% AE 7.8% in untreated or isotype control mAb-treated cultures, respectively, mean AE SE, n ¼ 6, P < 0.0001; Fig. 2B Research.
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Detection of ABCB5
þ VM morphology in clinical and experimental human melanomas Laminin-positive, PAS-positive patterned network VM morphology represents a biomarker associated with increased mortality in human melanoma patients (29) . We found that ABCB5, previously shown preferentially coexpressed with the VM markers CD144 and TIE1 in distributions distinct from CD31 þ mature tumor vessels (7), can be detected in clinical human melanomas (Fig. 3A) and in experimental xenografts established from patient-derived melanoma specimens (Fig. 3B ) or melanoma cell lines (Fig. 3C) . The patterned channel-like networks (33) were highlighted via immunochemical laminin reactivity, preferential cellular and spatial association of ABCB5 expression with secreted laminin reactivity in patterned networks as shown in immunofluorescence double-labeling studies (Fig. 3A-C, right) , and histochemical PAS reactivity (Fig. 3D) in vivo, consistent with established features of VM (27, 29) . Identical VM patterned networks of ABCB5 protein expression determined by protein immunohistochemistry (Fig. 3A-C) were also detected by ABCB5 mRNA ISH (Fig. 3E) . ABCB5 protein and mRNA expression also correlated significantly when assayed across a panel of human melanoma cell lines in vitro ( Supplementary  Fig. 1 ).
In further support of the preferential association of ABCB5 with VM, ABCB5 mAb, but not control Ig, administered intravenously to human melanoma xenograft-bearing mice showed specific binding to cell membranes of tumor cells in the pattern of anastomosing channels (Fig. 4A) , confirming the intimate association of ABCB5 þ melanoma cells with apparently communicating VM channel lumens. Conventional histology (Fig. 4B ) disclosed channels to be associated with linear lamellae of PAS-positive extracellular matrix (ECM; depicted in the inset, Fig. 4B ) intimately associated with tumor cells (highlighted with arrows, Fig. 4B ). Transmission electron microscopy of patientderived melanoma showed that conventional tumor angiogenesis (Fig. 4C, left) involved the formation of spaces lined by flattened endothelial cells, containing erythrocytes, and surrounded by tumor cells whereas other channels also containing erythrocytes were lined by ECM consistent with basement membrane [Fig. 4C , middle (arrows), Fig. 4C , right (asterisks)] and surrounded by tumor cells and thus were structurally consistent with "vasculogenic mimicry," as defined by Maniotis and colleagues (27) .
VEGFR-1 is required for in vivo VM and efficient tumor growth First, to confirm that VEGFR-1 is expressed on a tumorigenic subpopulation of ABCB5 þ melanoma cells, we investigated the tumorigenicity of purified VEGFR-1 þ and VEGFR-1 À melanoma subpopulations in vivo. VEGFR-1-dependent cell sorting was carried out by immunomagnetic selection as described (7) and groups of mice (n ¼ 14 replicates per group) were xenografted subcutaneously with VEGFR-1 þ or VEGFR-1 À melanoma cells representing 2 distinct patients and 1 To examine the functional role of VEGFR-1 in melanoma VM and to dissect mechanistically whether VEGFR-1 expressed by human melanoma cells is required for more efficient tumor growth, we next investigated the effects of selective VEGFR-1 knockdown in vivo. VEGFR-1 shRNA transfection (2 distinct shRNAs) of human melanoma cells derived from 3 melanoma patients and 2 melanoma cell lines inhibited VEGFR-1 mRNA expression by up to 93% (P < 0.01; Fig. 5C , top) and significantly blocked VEGFR-1 protein expression (Fig. 5D, bottom) . Patterned networks of ABCB5 þ VM expression were detected in tumors that formed from control shRNA-transfected melanoma inocula (Fig. 5D , top) but were not found, despite detectable, nonpatterned areas of ABCB5 positivity, in tumors that resulted from xenotransplantation of VEGFR-1 shRNAtransfected melanoma cells (Fig. 5D, bottom) . VM formation within tumors, also evaluated by quantitative image analysis technology (7) to assess the pixilated density of associated laminin immunoreactivity per cross-sectional area, was inhibited by 86% (Fig. 5E ) in tumors that formed from VEGFR-1 shRNA-transfected melanoma inocula compared with those that originated from controls (laminin immunoreactivity 0.8% AE 0.2% (n ¼ 6) versus 5.6% AE 1.9% (n ¼ 6), respectively; mean AE SE, P < 0.01). In contrast, VEGFR-1 knockdown in human melanoma cells exerted no significant effects on tumor angiogenesis, as determined by immunohistochemical staining for the marker of mature (murine) endothelium CD31, as documented via detection of conventional tubular, occasionally branching blood vessels (Fig. 5D) Fig. 5F ). The additional finding that VM laminin positivity correlated negatively with tumor size within the subset of untreated control tumors (Spearman rank correlation r ¼ À0.6) was consistent with a cause-and-effect relationship between inhibition of VEGFR-1-dependent laminin production and inhibition of tumor growth.
Discussion
Our study reveals several novel insights: First, ABCB5 þ MMICs previously found to be responsible for VM differ from melanoma bulk populations by preferentially expressing VEGFR-1. Second, VEGFR-1 signaling is required for MMICdependent VM differentiation and VM-associated laminin production. Finally, VEGFR-1 expression is required for efficient tumor growth.
VEGFR-1 is a tyrosine protein kinase and src oncogene family member and receptor for VEGF-A. When expressed by endothelial cells, VEGFR-1 regulates physiologic and pathologic angiogenesis (35) (36) (37) . In addition, VEGFR-1, when expressed by cells of the hematopoietic lineage, possesses angiogenesis-independent functions in malignant disease by enabling cancer host hematopoietic progenitors to establish premetastatic cell clusters and modulate ECM composition of the metastatic niche, resulting in enhanced tumor growth and metastasis (36, 38) . VEGF/VEGFR-1 signaling has previously been shown to function as an autocrine mechanism that can regulate tumor growth (39) . However, a malignant, growthpromoting role of preferentially tumor-initiating cellexpressed VEGFR-1 has not been described to date.
Consistent with previous reports (39, 40), we found VEGFR-1 to be expressed by human melanoma cells. Importantly, the present study revealed VEGFR-1 expression to be predominantly restricted to ABCB5 þ MMIC among human melanoma cells, which raised the possibility of a MMIC-related function of this receptor. Indeed, our study identifies VEGFR-1 signaling as a novel molecular mechanism responsible for MMICdependent VM and VM-associated laminin production (28, 41, 42) , a previously identified biomarker in human melanomas associated with aggressiveness (28) and increased clinical mortality (29) . Furthermore, our results show that functional VEGFR-1 expression by MMIC is required not only for melanoma VM and associated laminin production but also for more rapid tumorigenic growth, providing a potential explanation for the previously established correlation between VM and poor clinical prognosis in this malignancy. Mechanistically, our study indicates that VEGFR-1 knockdown-mediated inhibition of tumor growth resulted at least in part through blockade of MMIC-dependent laminin production, because this ECM constituent represents a potent melanoma mitogenic proliferative factor through defined signaling pathways (43) . It is noteworthy in this regard that laminin is also a key component of ECM preparations that exert potent protumorigenic effects when exogenously added to human melanoma grafts in experimental xenotransplantation models (22, 25) . Our demonstration that MMIC-expressed VEGFR-1 is required for tumor growth extends the known repertoire of tumor-initiating cell functions responsible for initiating or sustaining malignant progression, which include the tumorinitiating cell-defining functions of self-renewal, differentiation, and sustained proliferative capacity, as well as proangiogenic functions (25, 44) and immunomodulatory functions related to the evasion of host antitumor immunity (8, 25) .
Recently, proof-of-principle has been established for the potential therapeutic utility of targeting tumor-initiating cells, Research.
on April 20, 2017. © 2011 American Association for Cancer cancerres.aacrjournals.org Downloaded from including in human melanoma (7, 45, 46) . Therefore, the newly discovered role of VEGFR-1 function in MMIC-dependent tumorigenic growth is relevant to the design of novel MMICtargeted potential melanoma therapies. Specifically, our findings provide a rationale to investigate in future studies whether VEGFR-1-dependent, protumorigenic interactions of MMIC with VEGF-producing malignant or nonmalignant host cell populations in the tumor microenvironment can be specifically disrupted in a translationally relevant manner to inhibit tumor growth.
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